Table 1.
The 1-, 2-, and 5-year survivala for malignant brain and CNS tumors by histology and country.
| USb |
Taiwan |
|||||||
|---|---|---|---|---|---|---|---|---|
| 1-Year | 2-Year | 5-Year | 1-Year | 2-Year | 5-Year | |||
| Histology | N | Rate (95% CI) | Rate (95% CI) | Rate (95% CI) | N | Rate (95% CI) | Rate (95% CI) | Rate (95% CI) |
| Neuronal and mixed neuronal glial tumors | 82 | 94.7 (86.6–98.0) | 85.7 (74.9–92.0) | 71.3 (57.3–81.5) | 63 | 87.3 (76.2–93.4) | 71.4 (58.6–80.9) | 50.7 (37.4–62.6) |
| Ependymal tumors | 1,781 | 93.8 (92.6–94.9) | 89.3 (87.7–90.8) | 82.0 (79.8–84.1) | 177 | 88.1 (82.4–92.1) | 83.1 (76.7–87.8) | 69.0 (61.3–75.4) |
| Oligodendroglioma | 2,018 | 93.8 (92.6–94.8) | 89.6 (88.1–90.9) | 78.7 (76.5–80.8) | 283 | 91.9 (88.0–94.5) | 83.0 (78.1–86.9) | 70.3 (64.5–75.4) |
| Germ cell tumors, cysts, and heterotopias | 556 | 91.5 (88.8–93.6) | 89.0 (86.0–91.5) | 83.8 (79.8–87.0) | 263 | 92.0 (88.0–94.7) | 87.1 (82.4–90.6) | 81.2 (75.7–85.6) |
| Oligoastrocytic tumors | 1,345 | 88.1 (86.2–89.8) | 77.8 (75.3–80.1) | 62.8 (59.5–65.9) | 194 | 89.7 (84.5–93.2) | 77.3 (70.8–82.6) | 61.9 (54.3–68.6) |
| Anaplastic oligodendroglioma | 797 | 83.6 (80.8–86.1) | 72.2 (68.8–75.4) | 54.6 (50.4–58.6) | 150 | 82.7 (75.6–87.9) | 62.0 (53.7–69.2) | 35.4 (27.3–43.7) |
| Embryonal tumors | 1,738 | 81.6 (79.7–83.4) | 72.5 (70.2–74.7) | 60.9 (58.1–63.5) | 342 | 80.7 (76.1–84.5) | 69.3 (64.1–73.9) | 54.1 (48.6–59.4) |
| Meningioma | 684 | 79.3 (76.0–82.2) | 70.9 (67.2–74.3) | 59.4 (55.2–63.4) | 299 | 81.9 (77.1–85.9) | 66.9 (61.2–71.9) | 49.9 (43.9–55.6) |
| Nerve sheath tumors | 117 | 78.3 (69.4–84.9) | 71.4 (61.8–79.0) | 68.2 (58.3–76.2) | 23 | 60.9 (38.3–77.4) | 56.5 (34.3–73.8) | 52.2 (30.5–70.0) |
| Astrocytoma excluding GBM and AA | 4,101 | 73.4 (72.0–74.8) | 62.9 (61.3–64.4) | 48.8 (47.0–50.6) | 929 | 76.0 (73.1–78.6) | 63.6 (60.4–66.6) | 47.8 (44.5–51.1) |
| AA | 2,313 | 63.2 (61.1–65.1) | 44.8 (42.6–47.0) | 27.7 (25.5–29.9) | 447 | 67.8 (63.2–71.9) | 45.0 (40.3–49.5) | 22.1 (18.1–26.3) |
| Glioma malignant, NOS | 2,821 | 62.5 (60.6–64.3) | 51.9 (49.9–53.8) | 44.6 (42.6–46.7) | 293 | 63.8 (58.0–69.0) | 43.3 (37.6–48.9) | 32.5 (27.1–38.0) |
| CNS lymphoma | 2,898 | 51.4 (49.5–53.2) | 42.6 (40.7–44.5) | 31.5 (29.5–33.4) | 347 | 63.1 (57.8–68.0) | 47.6 (42.2–52.7) | 22.3 (17.8–27.1) |
| GBM | 19,893 | 37.5 (36.8–38.2) | 15.7 (15.2–16.3) | 5.0 (4.6–5.4) | 2,045 | 50.3 (48.1–52.4) | 24.0 (22.1–25.8) | 9.8 (8.5–11.2) |
| All values | 41,144 | 56.5 (56.0–57.0) | 41.1 (40.6–41.6) | 30.0 (29.5–30.5) | 5,855 | 68.1 (66.9–69.3) | 49.9 (48.6–51.2) | 34.3 (33.1–35.6) |
aRates are sorted from the largest to the smallest based on the 1-year US data.
bEstimated by CBTRUS using Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: incidence – SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, November 2013 Sub (1973–2011 varying) – Linked To County Attributes – Total US, 1969–2012 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2014, based on the November 2013 submission.
AA, anaplastic astrocytoma; CI, confidence interval; CNS, central nervous system; GBM, glioblastoma; NOS, not otherwise specified.